Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) posted 946 million yuan in profit attributable to shareholders of the listed company for the third quarter, up 15% from a year prior.
EPS moved 16.13% higher year over year to 0.36 yuan, a Tuesday filing with the Hong Kong Exchange showed.
For the three months ended Sept. 30, operating revenue was 10 billion yuan, an increase of 1.4% from the year-ago period, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.